Meet Our TeamInvestors and Industry Leaders
Prolong Pharmaceuticals is led by Dr. Sandeep Gupta, who was previously the Senior Vice-President of Discovery and Early Development, Endo Pharmaceuticals. Prior to Endo, Dr. Gupta spent a decade at Forest Laboratories as Head of Drug Discovery and Pharmacology. He played a key role in the development of several block buster drugs during his tenure at Endo and Forest. Before Forest Laboratories, Dr. Gupta held academic positions at the University of Pennsylvania and Boston University Schools of Medicine. Regarded as an architect of the Virtual Drug Discovery Research model, he has pioneered several successful Discovery and Development collaborations across the globe. He is a co-inventor on multiple patents and has authored over SO scientific papers, presentations and book chapters.
HEAD OF OPERATIONS
Dr. Chandra Rawal
Dr. Rawal has over 17 years of diversified manufacturing experience in various dosage forms, including oral solids, complex injectable, inhalation, and biologics. He has been instrumental in building infrastructures for cGMP manufacturing plants and building operational teams. Prior to his tenure with Kashiv, he headed global commercial manufacturing plants for Amneal Pharmaceuticals, and supported filing of applications for approval for multiple complex generic products in the US and EU markets. He has interacted with diverse cultures and has led international teams throughout the world. He has led many successful FDA and EU inspections throughout his career. He has a wide variety of industry experience in disciplines such as Clinical, Manufacturing, Commercialization, Quality and Project Management. Prior to entering the pharmaceutical industry, he was the Chief Medical Administrator for a chain of hospitals and was part of global quality accreditations, such as the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) and the National Accreditation Board for Hospitals & Healthcare Providers (NABH) in India. Dr. Rawal received his Doctor of Medicine (M.D.) from M.P. Shah Medical College in Jamnagar, Gujarat, India and his Masters in Healthcare Management from Central Michigan University (CMU).
VICE PRESIDENT – R&D
Dr. Ron Jubin
Dr. Jubin is Vice President of Research and Development at Prolong Pharmaceuticals and brings more than two decades of experience at the forefront of drug discovery. Ron’s experience includes key roles at Schering-Plough Research Institute and PBL Biomedical labs. At Schering-Plough, Dr. Jubin served in major roles in the hepatitis C protease program, directed other HCV inhibitor programs, and managed internal committees evaluating licensing opportunities for a novel interferon candidate. At PBL Biomedical, his tenure leading the Research and Development department at PBL resulted in the development of numerous interferon proteins, reagents, and functional assay for evaluating immune and interferon functions. Dr. Jubin received his PhD in Microbiology and Molecular Genetics from the UMDNJ-NJMS Graduate School of Biomedical Sciences, Newark, NJ.
SENIOR VICE PRESIDENT – REGULATORY
John has over 30 years’ experience in regulatory affairs in the development and maintenance of novel drugs, biologics, 505(b)(2) products, and biosimilars. Over the past 10 years, he has been a leader in global regulatory affairs for biosimilars and helped shape the biosimilar pathway in the US. He has served as Vice Chairman of the Biosimilar Council, Chair of the Association of Accessible Medicines (AAM) Biosimilars Working Group prior to the establishment of the Council, Chair of the Biosimilar Forum Regulatory Committee, and represented AAM during both Biosimilar User Fee Negotiations with FDA. Under his leadership at Mylan, the first biosimilar (trastuzumab) was approved in the U.S., two Biologics License Applications (BLAs) and 505(b)(2) biologics New Drug Applications (NDAs) were submitted to the U.S. F.D.A., and three Market Authorization Applications (MAAs) were submitted to the European Medicines Agency (EMA). He headed U.S. Biopharmaceutical Regulatory Affairs at Sandoz Inc., where he was involved with the approval of the first biosimilar in the US and with the submission of two additional biosimilar BLAs. Prior to his involvement with biosimilars, he worked for over 20 years on novel drugs and biologics, and 505(b)(2) products in roles of increasing responsibility within global and U.S. regulatory affairs at Pfizer, Aventis, and Sanofi. He has broad experience on the regulatory aspects of the technical and clinical development for drugs and biologics in a variety of therapeutic areas. John is a pharmacist and graduate of Rutgers College of Pharmacy.
Avtar Investments is a single-family office with decades of experience investing in healthcare assets including pharmaceuticals, health technology and healthcare services.
If you have any questions regarding our products or services, please contact us by phone or by completing the contact form and we will respond to your inquiry at the earliest convenience.
300 Corporate Court, Suite B
South Plainfield, NJ 07080 USA
Expanded Access Policy
Prolong Pharmaceuticals, LLC does not provide any drug in development to patients unless they have been accepted into one of our ongoing clinical trials. For more information on our ongoing clinical trials, please contact email@example.com